VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM

NCT03149575 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Change in clinical development plan

Conditions

Glioblastoma Multiforme
Glioblastoma
Glioma
GBM
Brain Cancer

Interventions

DRUG: VAL-083, Dianhydrogalactitol
DRUG: Physician's Choice of Salvage Therapy - temozolomide
DRUG: Physician's Choice of Salvage Therapy - lomustine
DRUG: Physician's Choice of Salvage Therapy - carboplatin

Sponsor

DelMar Pharmaceuticals, Inc.